🚀 VC round data is live in beta, check it out!
Bioventix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bioventix and similar public comparables like Pacific Edge, SDI Group, 4basebio, ArcticZymes and more.
Bioventix Overview
About Bioventix
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
Founded
2003
HQ
Employees
16
Website
Sectors
Financials (LTM)
EV
$122M
Bioventix Financials
Bioventix reported last 12-month revenue of $17M and EBITDA of $13M.
In the same LTM period, Bioventix generated $15M in gross profit, $13M in EBITDA, and $10M in net income.
Revenue (LTM)
Bioventix P&L
In the most recent fiscal year, Bioventix reported revenue of $18M and EBITDA of $14M.
Bioventix expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $17M | XXX | $18M | XXX | XXX | XXX |
| Gross Profit | $15M | XXX | $16M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $13M | XXX | $14M | XXX | XXX | XXX |
| EBITDA Margin | 76% | XXX | 78% | XXX | XXX | XXX |
| EBIT Margin | 75% | XXX | 77% | XXX | XXX | XXX |
| Net Profit | $10M | XXX | $10M | XXX | XXX | XXX |
| Net Margin | 58% | XXX | 58% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bioventix Stock Performance
Bioventix has current market cap of $129M, and enterprise value of $122M.
Market Cap Evolution
Bioventix's stock price is $24.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $122M | $129M | -0.5% | XXX | XXX | XXX | $1.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioventix Valuation Multiples
Bioventix trades at 7.2x EV/Revenue multiple, and 9.5x EV/EBITDA.
EV / Revenue (LTM)
Bioventix Financial Valuation Multiples
As of April 14, 2026, Bioventix has market cap of $129M and EV of $122M.
Equity research analysts estimate Bioventix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioventix has a P/E ratio of 13.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $129M | XXX | $129M | XXX | XXX | XXX |
| EV (current) | $122M | XXX | $122M | XXX | XXX | XXX |
| EV/Revenue | 7.2x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 9.5x | XXX | 9.0x | XXX | XXX | XXX |
| EV/EBIT | 9.6x | XXX | 9.1x | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | 7.7x | XXX | XXX | XXX |
| P/E | 13.2x | XXX | 12.7x | XXX | XXX | XXX |
| EV/FCF | 12.3x | XXX | 12.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bioventix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bioventix Margins & Growth Rates
Bioventix's revenue in the last 12 month declined by (1%).
Bioventix's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.2M for the same period.
Bioventix's rule of 40 is 74% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioventix's rule of X is 71% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Bioventix Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (1%) | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | 76% | XXX | 78% | XXX | XXX | XXX |
| EBITDA Growth | (1%) | XXX | (6%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 74% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 71% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 16% | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bioventix Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bioventix | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacific Edge | XXX | XXX | XXX | XXX | XXX | XXX |
| SDI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| ArcticZymes | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Teknova | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioventix M&A Activity
Bioventix acquired XXX companies to date.
Last acquisition by Bioventix was on XXXXXXXX, XXXXX. Bioventix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bioventix
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioventix Investment Activity
Bioventix invested in XXX companies to date.
Bioventix made its latest investment on XXXXXXXX, XXXXX. Bioventix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bioventix
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bioventix
| When was Bioventix founded? | Bioventix was founded in 2003. |
| Where is Bioventix headquartered? | Bioventix is headquartered in United Kingdom. |
| How many employees does Bioventix have? | As of today, Bioventix has over 16 employees. |
| Who is the CEO of Bioventix? | Bioventix's CEO is Peter John Harrison. |
| Is Bioventix publicly listed? | Yes, Bioventix is a public company listed on London Stock Exchange. |
| What is the stock symbol of Bioventix? | Bioventix trades under BVXP ticker. |
| When did Bioventix go public? | Bioventix went public in 2014. |
| Who are competitors of Bioventix? | Bioventix main competitors are Pacific Edge, SDI Group, 4basebio, ArcticZymes. |
| What is the current market cap of Bioventix? | Bioventix's current market cap is $129M. |
| What is the current revenue of Bioventix? | Bioventix's last 12 months revenue is $17M. |
| What is the current revenue growth of Bioventix? | Bioventix revenue growth (NTM/LTM) is (1%). |
| What is the current EV/Revenue multiple of Bioventix? | Current revenue multiple of Bioventix is 7.2x. |
| Is Bioventix profitable? | Yes, Bioventix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bioventix? | Bioventix's last 12 months EBITDA is $13M. |
| What is Bioventix's EBITDA margin? | Bioventix's last 12 months EBITDA margin is 76%. |
| What is the current EV/EBITDA multiple of Bioventix? | Current EBITDA multiple of Bioventix is 9.5x. |
| What is the current FCF of Bioventix? | Bioventix's last 12 months FCF is $10M. |
| What is Bioventix's FCF margin? | Bioventix's last 12 months FCF margin is 59%. |
| What is the current EV/FCF multiple of Bioventix? | Current FCF multiple of Bioventix is 12.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.